Compare Stocks: ZVRA, MOR, ATAI, and SUPN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.33 +0.6%	$6.81	$3.27 ▼ $7.45	$2.72B	1.54	8.45 million shs	3.25 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
SUPN Supernus Pharmaceuticals	$41.78 -1.5%	$46.54	$41.76 ▼ $59.68	$2.43B	0.56	746,283 shs	146,268 shs
ZVRA Zevra Therapeutics	$12.24 -3.5%	$11.98	$7.16 ▼ $15.03	$727.99M	0.95	1.30 million shs	371,097 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	-1.49%	-0.82%	+0.41%	+92.59%	+61.06%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
SUPN Supernus Pharmaceuticals	-2.53%	-2.99%	-10.94%	-5.90%	-7.40%
ZVRA Zevra Therapeutics	+2.26%	+5.14%	+9.69%	-6.07%	+52.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.33 +0.6%	$6.81	$3.27 ▼ $7.45	$2.72B	1.54	8.45 million shs	3.25 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
SUPN Supernus Pharmaceuticals	$41.78 -1.5%	$46.54	$41.76 ▼ $59.68	$2.43B	0.56	746,283 shs	146,268 shs
ZVRA Zevra Therapeutics	$12.24 -3.5%	$11.98	$7.16 ▼ $15.03	$727.99M	0.95	1.30 million shs	371,097 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	-1.49%	-0.82%	+0.41%	+92.59%	+61.06%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
SUPN Supernus Pharmaceuticals	-2.53%	-2.99%	-10.94%	-5.90%	-7.40%
ZVRA Zevra Therapeutics	+2.26%	+5.14%	+9.69%	-6.07%	+52.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Beckley	2.06	Hold	$10.56	44.11% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	2.43	Hold	$62.83	50.39% Upside
ZVRA Zevra Therapeutics	2.90	Moderate Buy	$27.14	121.76% Upside

Current Analyst Ratings Breakdown

Latest ZVRA, MOR, ATAI, and SUPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/20/2026	ZVRA Zevra Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
8/19/2026	ZVRA Zevra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/17/2026	ATAI Atai Beckley	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/13/2026	ATAI Atai Beckley	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	ATAI Atai Beckley	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $8.00
8/12/2026	ATAI Atai Beckley	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $8.00
8/7/2026	ZVRA Zevra Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $23.00
8/6/2026	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Beckley	$4.47M	607.47	N/A	N/A	$0.69 per share	10.62
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
SUPN Supernus Pharmaceuticals	$718.95M	3.38	$3.62 per share	11.53	$18.52 per share	2.26
ZVRA Zevra Therapeutics	$136.07M	5.34	$0.93 per share	13.11	$2.75 per share	4.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Beckley	-$660.05M	-$2.18	N/A	N/A	N/A	-14,938.36%	-88.30%	-58.88%	11/12/2026 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
SUPN Supernus Pharmaceuticals	-$38.55M	-$1.92	N/A	10.82	0.80	-13.23%	11.13%	8.10%	11/3/2026 (Estimated)
ZVRA Zevra Therapeutics	$83.23M	$0.92	13.33	14.57	N/A	42.82%	54.54%	34.15%	11/4/2026 (Estimated)

Latest ZVRA, MOR, ATAI, and SUPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ATAI Atai Beckley	-$0.1075	-$0.09	+$0.0175	-$0.09	$0.60 million	$1.70 million
8/5/2026	Q2 2026	ZVRA Zevra Therapeutics	$0.11	$0.25	+$0.14	$0.14	$33.88 million	$39.66 million
8/3/2026	Q2 2026 & Merger	SUPN Supernus Pharmaceuticals	$0.4225	-$1.01	-$1.4325	-$1.01	$205.31 million	$219.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Beckley	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Beckley	N/A	N/A	N/A
MOR MorphoSys	4.98	1.38	1.38
SUPN Supernus Pharmaceuticals	N/A	2.08	1.84
ZVRA Zevra Therapeutics	N/A	5.17	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Beckley	28.41%
MOR MorphoSys	18.38%
SUPN Supernus Pharmaceuticals	N/A
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ATAI Atai Beckley	19.80%
MOR MorphoSys	0.05%
SUPN Supernus Pharmaceuticals	8.50%
ZVRA Zevra Therapeutics	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Beckley	80	370.87 million	297.43 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
SUPN Supernus Pharmaceuticals	580	58.13 million	53.19 million	Optionable
ZVRA Zevra Therapeutics	20	59.38 million	57.19 million	Optionable

ZVRA, MOR, ATAI, and SUPN Headlines

Recent News About These Companies

Bank of America Corp DE Decreases Stock Position in Zevra Therapeutics, Inc. $ZVRA

September 8 at 3:13 AM | marketbeat.com

Bank of New York Mellon Corp Invests $2.85 Million in Zevra Therapeutics, Inc. $ZVRA

September 7 at 3:43 AM | marketbeat.com

Zevra Therapeutics to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium

August 25, 2026 | quiverquant.comQ

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

August 25, 2026 | globenewswire.com

Globeflex Capital L P Invests $2.75 Million in Zevra Therapeutics, Inc. $ZVRA

August 24, 2026 | marketbeat.com

Roth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

August 23, 2026 | theglobeandmail.com

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | globenewswire.com

Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright

August 20, 2026 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages

August 19, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 13, 2026 | prnewswire.com

Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock

August 12, 2026 | marketbeat.com

Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA

August 12, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 11, 2026 | globenewswire.com

Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA

August 10, 2026 | marketbeat.com

HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings

August 10, 2026 | marketbeat.com

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

August 7, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 6, 2026 | prnewswire.com

Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041

August 6, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

August 5, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZVRA, MOR, ATAI, and SUPN Company Descriptions

Atai Beckley NASDAQ:ATAI

$7.32 +0.05 (+0.62%)

As of 12:51 PM Eastern

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 09/8/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Supernus Pharmaceuticals NASDAQ:SUPN

$41.78 -0.65 (-1.53%)

As of 12:32 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Zevra Therapeutics NASDAQ:ZVRA

$12.24 -0.44 (-3.47%)

As of 12:51 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZVRA, MOR, ATAI, and SUPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZVRA, MOR, ATAI, and SUPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZVRA, MOR, ATAI, and SUPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZVRA, MOR, ATAI, and SUPN Company Descriptions

Atai Beckley NASDAQ:ATAI

MorphoSys NASDAQ:MOR

Supernus Pharmaceuticals NASDAQ:SUPN

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZVRA, MOR, ATAI, and SUPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZVRA, MOR, ATAI, and SUPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZVRA, MOR, ATAI, and SUPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZVRA, MOR, ATAI, and SUPN Company Descriptions

Atai Beckley NASDAQ:ATAI

MorphoSys NASDAQ:MOR

Supernus Pharmaceuticals NASDAQ:SUPN

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools